Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Nuvation Bio Inc (NYSE: NUVB) closed the day trading at $5.15 down -2.09% from the previous closing price of $5.26. In other words, the price has decreased by -$2.09 from its previous closing price. On the day, 11.44 million shares were traded. NUVB stock price reached its highest trading level at $5.4 during the session, while it also had its lowest trading level at $5.11.
Ratios:
For a better understanding of NUVB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.38 and its Current Ratio is at 9.39. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.52.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Jefferies on September 30, 2025, initiated with a Buy rating and assigned the stock a target price of $10.
On April 23, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $6.
Jefferies Upgraded its Hold to Buy on March 27, 2024, whereas the target price for the stock was revised from $1.40 to $10.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 27 ’25 when Hattersley Gary sold 100,000 shares for $5.02 per share. The transaction valued at 502,460 led to the insider holds 0 shares of the business.
GARY HATTERSLEY bought 100,000 shares of NUVB for $485,000 on Oct 27 ’25. On Jun 18 ’25, another insider, Markel Stacy, who serves as the CHIEF PEOPLE OFFICER of the company, bought 10,000 shares for $1.71 each. As a result, the insider paid 17,100 and bolstered with 29,591 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NUVB now has a Market Capitalization of 1762704640 and an Enterprise Value of 1212746496. For the stock, the TTM Price-to-Sale (P/S) ratio is 123.11 while its Price-to-Book (P/B) ratio in mrq is 4.67. Its current Enterprise Value per Revenue stands at 84.483 whereas that against EBITDA is 6.019.
Stock Price History:
The Beta on a monthly basis for NUVB is 1.53, which has changed by 1.2391305 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, NUVB has reached a high of $5.55, while it has fallen to a 52-week low of $1.54. The 50-Day Moving Average of the stock is 43.65%, while the 200-Day Moving Average is calculated to be 102.99%.
Shares Statistics:
Over the past 3-months, NUVB traded about 6.80M shares per day on average, while over the past 10 days, NUVB traded about 10525190 shares per day. A total of 336.84M shares are outstanding, with a floating share count of 231.51M. Insiders hold about 32.56% of the company’s shares, while institutions hold 53.64% stake in the company. Shares short for NUVB as of 1760486400 were 79205983 with a Short Ratio of 11.64, compared to 1757894400 on 68015555. Therefore, it implies a Short% of Shares Outstanding of 79205983 and a Short% of Float of 37.75.
Earnings Estimates
The performance of Nuvation Bio Inc (NUVB) in the stock market is under the watchful eye of 1.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.13 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.55 and -$0.55 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.52, with 1.0 analysts recommending between -$0.52 and -$0.52.
Revenue Estimates
5 analysts predict $6.86M in revenue for. The current quarter. It ranges from a high estimate of $10.3M to a low estimate of $4.43M. As of. The current estimate, Nuvation Bio Inc’s year-ago sales were $727kFor the next quarter, 5 analysts are estimating revenue of $16.24M. There is a high estimate of $31.5M for the next quarter, whereas the lowest estimate is $8.76M.
A total of 7 analysts have provided revenue estimates for NUVB’s current fiscal year. The highest revenue estimate was $52.9M, while the lowest revenue estimate was $21.1M, resulting in an average revenue estimate of $32.98M. In the same quarter a year ago, actual revenue was $7.87MBased on 7 analysts’ estimates, the company’s revenue will be $137.58M in the next fiscal year. The high estimate is $209.59M and the low estimate is $79.1M.
